Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Researchers Identify Novel Class of Drugs for Prostate Cancers

Published: Wednesday, May 29, 2013
Last Updated: Wednesday, May 29, 2013
Bookmark and Share
A new study on prostate cancer describes a novel class of drugs that interrupts critical signaling needed for prostate cancer cells to grow.

In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling, which is driven by androgens, such as testosterone. To thwart tumor growth, most patients with advanced prostate cancer receive drugs that block the production of androgen or block the receptor where the androgen binds. Unfortunately, such treatments invariably fail and patients die of prostate cancer with their androgen receptor signaling still active and still promoting tumor growth.

In the new study, available online at Nature Communications, a team of researchers led by Dr. Ganesh Raj, associate professor of urology at UT Southwestern, found that they could disrupt androgen receptor signaling using a novel class of drugs called peptidomimetics. This therapeutic agent consists of an engineered small protein-like chain designed to mimic peptides that are critical for androgen receptor function. The peptidomimetic agents block the activity of the androgen receptor even in the presence of androgen by attacking the protein in a different spot from where the androgen binds.

“We are hopeful that this novel class of drugs will shut down androgen receptor signaling and lead to added options and increased longevity for men with advanced prostate cancer,” said Dr. Raj, the senior author of the study.

Dr. Raj compared the action that takes place to a lock and key mechanism. In prostate cancer, the androgen receptor (lock) is activated by the androgen (key) resulting in a signal that causes prostate cancer proliferation. In advanced prostate cancer, despite drugs targeting either the lock (androgen receptor) or the key (androgen production), there can be aberrant keys that open the lock or mutated locks that are always open, resulting in cancer cell proliferation. Instead of trying to block the lock or the key, peptidomimetics uncouple the lock and key mechanism from the proliferation signal. Thus, even with the androgen receptor activated, the prostate cancer cells do not receive the signal to proliferate and do not grow.

The researchers tested their drug in mouse and human tissue models. The novel drug proved non-toxic and prevented androgen receptor signaling in cancer cells. The response is highly promising and suggests that peptidomimetic targeting of prostate cancer may be a viable therapeutic approach for men with advanced disease.

Further testing is needed before a drug could move to Phase 1 clinical trials that involve human participants.

“Most drugs now available to treat advanced prostate cancer improve survival rates by three or four months,” Dr. Raj said. “Our new agents may offer hope for men who fail with the current drugs.”

These findings represent the development of a first-in-class agent targeting critical interactions between proteins. Other cellular and disease processes eventually could also be targeted with peptidomimetics, the scientists said.

Other UT Southwestern researchers involved in the study are Preethi Ravindranathan, a technician in Dr. Raj’s laboratory, Dr. Jer-Tsong Hsieh, professor of urology, and Dr. Jung-Mo Ahn, visiting associate professor of urology. Researchers from University of Texas at Dallas; the First Affiliated Hospital of Medical College of Xi’an Jiaotong University, Urology Institute of Xi’an Jiaotong University; Dame Roma Mitchell Cancer Research Laboratories and Adelaide Prostate Cancer, Research Center, University of Adelaide and Hanson Institute also contributed to the research.

The Prostate Cancer Foundation, the Dorothy and James Cleo Thompson Foundation, and the Robert A. Welch Foundation funded the research.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Blocking DNA Repair Mechanisms Could Improve Brain Cancer Therapy
The findings were published April 7 in Nature Communications.
Saturday, April 12, 2014
Study Identifies Potential Therapeutic Target for Incurable, Rare Type of Soft-Tissue Cancer
UT Southwestern scientists study published online in Cell Reports.
Friday, December 27, 2013
Rapid Bone Loss Possible Side Effect of Anti-Obesity Drug
Research from UT Southwestern Medical Center has raised concern about the safe use of fibroblast growth factor 21.
Tuesday, February 07, 2012
Experimental Drug Shows Promise Against Brain, Prostate Cancers, UT Southwestern Researchers Find
Study shows that drug attacked not only the bulk of the tumor cells but also the rare cancer stem cells responsible for cancer’s growth.
Wednesday, January 06, 2010
UT Southwestern Aids National Effort to Recruit Volunteers for Medical Research
A new national initiative will match volunteers who want to take part in medical research studies with the scientists who are leading those studies.
Thursday, November 19, 2009
UT Southwestern Researchers Use Drug-Radiation Combo to Eradicate Lung Cancer
Researchers have eliminated non-small cell lung cancer in mice by using an investigative drug called BEZ235 in combination with low-dose radiation.
Friday, November 06, 2009
NIH Funds New Virus Database at UT Southwestern
The $15.7 million contract will develop an open-access national online database and analysis resource center that will help scientists study and combat pathogenic viruses.
Wednesday, October 14, 2009
Gene Linked to Lupus Might Explain Gender Difference in Disease Risk
In an international human genetic study, researchers at UT Southwestern Medical Center have identified a gene linked to the autoimmune disease lupus, and its location on the X chromosome might help explain why females are 10 times more susceptible to the disease than males.
Monday, March 30, 2009
Fat-Free Diet Reduces Liver Fat in Fat-Free Mice, UT Southwestern Researchers Report
Researchers have uncovered crucial clues about a paradoxical disease in which patients with no body fat develop many health complications.
Thursday, February 05, 2009
Cancer Requires Support From Immune System to Develop, UT Southwestern Researchers Report
Tumors that grow around nerves in a rare genetic disease need cooperation from cells from the immune system in order to grow, reports a team of scientists, including researchers from UT Southwestern Medical Center.
Thursday, October 30, 2008
Gene Variant Boosts Risk of Fatty Liver Disease
Researchers at UT Southwestern Medical Center have found that individuals who carry a specific form of the gene PNPLA3 have more fat in their livers and a greater risk of developing liver inflammation.
Friday, September 26, 2008
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Study Questions Presence in Blood of Heart-Healthy Molecules from Fish Oil Supplements
A new study from the Perelman School of Medicine at the University of Pennsylvania questions the relevance of fish oil-derived SPMs and their purported anti-inflammatory effects in humans.
Experimental MERS Vaccine Shows Promise in Animal Studies
A two-step regimen of experimental vaccines against Middle East respiratory syndrome (MERS) prompted immune responses in mice and rhesus macaques, report National Institutes of Health scientists who designed the vaccines.
Young South African Women can Adhere to Daily PrEP Regimen as HIV Prevention
NIH-funded study finds men in Bangkok, Harlem also successful in taking daily dose.
Key Player in Diabetic Kidney Disease Revealed
Discovery could lead to new and better diagnostic marker for chronic kidney disease.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Santhera Announces First Patient Dosing with Omigapil in CMD
Company announces full patient recruitment of CALLISTO study.
Study Shows Promise of Precision Medicine for Most Common Type of Lymphoma
The study appeared online July 20, 2015, in Nature Medicine.
HIV Control Through Treatment Durably Prevents Heterosexual Transmission of Virus
NIH-funded trial proves suppressive antiretroviral therapy for HIV-infected people effective in protecting uninfected partners.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!